Alain Mina

[Alain Mina @dralainmina]

Serving at the NIH was by far one of the greatest honors of my career… @NIH @theNCI

[Yale Cancer Center @YaleCancer]

Tomorrow starting at 11am CEST/5am EST at @EHA_Hematology EHA Congress, @Dr_AmerZeidan and Dr. Nikolai Podolsev will present study results during the 'Novel Treatments in #AML' session at #EHA26.
https://t.co/EswbXuTz9H
@SmilowCancer @YaleHematology

[Alain Mina @dralainmina]

@MinaXu7 Happiest Birthday Mina! Great team reflects a great leader

[Yale Hematology Oncology Fellows @YaleHemOnc]

One of the greats! So proud to have Nikolai as our APD 🥇🍾

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

We had an outstanding brainstorming/strategic planning meeting fin the leukemia program within @YaleCancer @YaleHematology including clinical, translational, registry-based & HOER projects in #AMLsm #MDSsm #MPNsm & involving many residents, fellows, trainees & other team members

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

We had a nice event to celebrate three of our malignant hematology colleagues who will be leaving Yale: our amazing transplant APP Alfredo Axtmayer to join industry, our postdoc Luca Lanino who will be joining DFCI for a leukemia fellowship, and our graduating heme/onc fellow Ted Getz who will be joining leukemia faculty at NYU. We also welcomed our two graduating fellows who will be joining our malignant heme faculty in the lymphoma program Etienne Leveille and Cristian Taborda.

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

🎤 JUST ANNOUNCED: THE MXH 2026 FACULTY LINEUP! Join leading experts on July 11–12 at the Conrad New York Downtown for latest data, expert debates, & practical insights to bring back to your practice. Secure free registration with code zeidan at: https://t.co/jxSYzK8sXI

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

I look forward to this very important presentation in #EHA2026 about value of transplant in TP53 mutated #MDSsm and #AMLsm. The results clearly indicate a tail at end of curve and around 20% 23-year OS even among biallelic TP53mut patients, and especially in those with lower blast counts. Do NOT deprive patients from the opportunity of transplant without a very well-informed discussion!

Patients with KPS >80 had an estimated 3-year OS of 49.3%, compared with 30.2% for KPS ≤80. Biallelic TP53 was associated with inferior survival (HR 4.05, 95% CI 1.76–9.32; p=0.001) (figure 1b), reaching statistical significance only in the MDS subgroup. A low blast count at diagnosis was associated with improved survival (HR 0.50, 95% CI 0.29–0.88; p=0.02).

No clear associations were observed for age, HCT-CI, donor type, conditioning intensity or ATG. NRM did not differ significantly between MDS and AML (figure 1c).

ALLOGENEIC HSCT FOR TP53-ABERRANT MYELOID NEOPLASMS: REAL-WORLD... - Myhre A - EHA-6995 - Jun 13 2026

[Alain Mina @dralainmina]

@mumairmushtaq @Dr_AmerZeidan @KUcancercenter @KUMedCenter @mrf_org @USMIRCNEWS Great effort! Congrats! What’s next for the product with VOR restructuring?

[Emma M. Groarke @emmamgroarke]

Super excited to share our How-I-Treat our today in @BloodPortfolio where we show how we integrate somatic mutations and other alterations 🧬 into the diagnosis and clinical care of #BMFsm patients. @fergutierrezro1 @bhavishap29 @NIH https://t.co/CnSeDfvc7E

[Alain Mina @dralainmina]

@Dr_AmerZeidan @MedwatchKate If fit enough for a transplant, triplet to induce as deep a remission as possible. If not, I would stretch out the therapies as long as possible.

[Mina L Xu @MinaXu7]

Honored to be among the doctors recognized for our clinical work for cancer patients here. We hope to do even better in the future through research.

[Alain Mina @dralainmina]

@MinaXu7 @RongFan8 @miltenyibiotec Sorry I missed it :/

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

Glad to share our @Yale tour-de-force review of #MDSsm published in @Nature Reviews of Clinical Oncology (Free online read at https://t.co/GTWWl9intQ) which has to be the most comprehensive review we have ever written on the subject covering all relevant areas from epidemiology, pathogenesis, diagnosis, risk stratification, to current and evolving therapies for lower and higher risk disease @YaleCancer @YaleHematology @YaleMed

[Alain Mina @dralainmina]

@YaleCancer @YaleHematology Amazing!

[Yale Cancer Center @YaleCancer]

New study led by Dr. Luca Lanino @YaleHematology analyzes the genomics of chronic myelomonocytic leukemia through a large international collaboration, identifying 9 molecular subtypes of #CMML and introducing #iCPSS, a genomics-based risk calculator to improve prognosis and guide treatment planning (https://t.co/V1f013x0iK)

https://t.co/gUu1pOLmVf
@Dr_AmerZeidan @SmilowCancer @JCO_ASCO

[Alain Mina @dralainmina]

@Dr_AmerZeidan @YaleCancer @YaleHematology @Yale @YaleMed @YaleMedicine Always wonderful partnering with you Amer. Let’s keep creating.

[Amer Zeidan عامر زيدان @Dr_AmerZeidan]

Our newest paper led by our own @dralainmina on the Pharmacologic progress in higher-risk MDS (or lack of): an uphill battle @YaleCancer @YaleHematology @Yale @YaleMed @YaleMedicine https://t.co/7lDZSWfrQa

[Kate Sears @MedwatchKate]

2️⃣ Permissive HLA-DPB1 Mismatch with PTCy Reduces Relapse in High-Risk AML/MDS

Allo transplant donor selection in high-risk AML/MDS may be optimized by allowing permissive HLA-DPB1 mismatches when using PTCy. In a Leukemia study, permissive DPB1 mismatches were associated with lower relapse vs fully matched donors (2-year: 18% vs 28%; HR 0.6), with the greatest benefit in high-risk disease.
https://t.co/WpclgfE9zI

[Yale Cancer Center @YaleCancer]

A great morning of presentations at our annual post-ASH meeting hosted by @NataliaNeparid1 Thoughtful questions & excellent talks highlighting new data and exciting #clinicaltrials for patients with hematologic malignancies. @YaleHematology @MaxStahlMD @Dr_AmerZeidan #ASH25.